[Therapeutic use of cannabis derivatives].
The therapeutic use of cannabis has generated a lot of interest in the past years, leading to a better understanding of its mechanisms of action. Countries like the United States and Canada have modified their laws in order to make cannabinoid use legal in the medical context. It's also the case in France now, where a recent decree was issued, authorizing the prescription of medication containing "therapeutic cannabis" (decree no. 2013-473, June 5, 2013). Cannabinoids such as dronabinol, Sativex and nabilone have been tested for the treatment of acute and chronic pain. These agents are most promising to relieve chronic pain associated with cancer, with human immunodeficiency virus infection and with multiple sclerosis. However, longer-term studies are required to determine potential long-term adverse effects and risks of misuse and addiction.
Amine
A
Benyamina
Michel
M
Reynaud
D000932:Antiemetics / Q000627:therapeutic use; D002185:Cannabidiol; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004338:Drug Combinations; D005356:Fibromyalgia / Q000188:drug therapy; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D009128:Muscle Spasticity / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D010936:Plant Extracts / Q000627:therapeutic use*
D000932:Antiemetics; D004338:Drug Combinations; D010936:Plant Extracts; D002185:Cannabidiol; C011941:nabilone; D013759:Dronabinol; C587251:nabiximols